To include your compound in the COVID-19 Resource Center, submit it here.

Tivozanib: Phase III ongoing

Aveo said it does not expect data from the open-label, international Phase III TIVO-1 trial of tivozanib until 4Q11

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE